# Milestone-based venture philanthropy with royalties recycled into the pipeline

Source: https://onco.cc/ideas/idea-fund-milestone-venture-philanthropy/  
OnCo record `idea-fund-milestone-venture-philanthropy` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cancer charities would fund companies to hit specific development milestones, as the cystic fibrosis charity did to create Kalydeco, and take a royalty they reinvest in the next drug.

## Summary

Disease foundations move from grant-giving to milestone-based development contracts with biotech and pharma: payments are released on defined preclinical and clinical milestones for an agreed indication (for example a rare sarcoma, a paediatric brain tumour, cachexia), the foundation receives royalties or equity, and returns are recycled. The Cystic Fibrosis Foundation's investment in Vertex produced ivacaftor and returned more than $3 billion through a royalty sale; the Leukemia and Lymphoma Society's Therapy Acceleration Program and the Multiple Myeloma Research Foundation have applied versions of this in blood cancers. Solid tumours and paediatric cancers have few such programmes at scale.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A consortium of cancer foundations deploying $300 million in milestone contracts over five years produces at least two registration-stage programmes in indications with no prior industry activity and a royalty stream sufficient to sustain the programme.
- Rationale: Milestone contracts change what companies work on because the foundation absorbs early risk and brings patients, registries and clinical networks; blood cancer foundations attribute several approvals to this approach. Charity money used this way is leveraged several-fold by subsequent private investment.
- Proposed test: Two foundations pool a fund with a professional deal team, sign milestone contracts for five programmes, and report milestones achieved, follow-on capital raised and royalties at years three and six.
- Maturity: early-clinical
- Actor: philanthropy

## Sources

- Cystic Fibrosis Foundation: https://www.cff.org/
- LLS Therapy Acceleration Program: https://www.lls.org/therapy-acceleration-program

## Connected records

- ideas: [A diversified royalty pool that finances academic phase 1 trials across fifty assets](https://onco.cc/ideas/idea-fund-royalty-pool-academic-assets/), [A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks](https://onco.cc/ideas/idea-fund-ind-enabling-fund/), [A non-profit pharmaceutical company for the cancers markets ignore](https://onco.cc/ideas/idea-fund-nonprofit-pharma/), [Advance market commitments for paediatric and rare cancer drugs](https://onco.cc/ideas/idea-fund-amc-paediatric-rare/)
- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- bottlenecks: [Rare and paediatric cancers without markets](https://onco.cc/bottlenecks/b-rare-cancers/), [The valley of death between lab and product](https://onco.cc/bottlenecks/b-translational-valley/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-milestone-venture-philanthropy.json